bioRxivPharmacology & ToxicologyPreprint
Establishment and application of unbiased in vitro drug screening assays for the identification of compounds against Echinococcus granulosus s.s.
M. Kaethner, M. Preza, T. Kaempfer, P. Zumstein, C. Tamponi, A. Varcasia, A. Hemphill, K. Brehm, B. Lundström-Stadelmann
Abstract
Echinococcus multilocularis and E. granulosus s.l. are the causative agents of alveolar and cystic echinococcosis, respectively. Drug treatment options for these severe and neglected diseases are limited to benzimidazoles, which are not always efficacious, and adverse side effects are reported. Thus, novel and improved treatments are needed. In this study, the previously established platform for E. multilocularis in vitro drug assessment was adapted to E. granulosus s.s.. In a first step, in vitro culture protocols for E. granulosus s.s. were established. This resulted in the generation of large amounts of E. granulosus s.s. metacestode vesicles as well as germinal layer (GL) cells. In vitro culture of these cells formed metacestode vesicles displaying structural characteristics of metacestode vesicles generated in vivo. Next, drug susceptibilities of E. multilocularis and E. granulosus s.s. protoscoleces, metacestode vesicles and GL cells were comparatively assessed employing established assays including (i) metacestode vesicle damage marker release assay, (ii) metacestode vesicle viability assay, (iii) GL cell viability assay, and (iv) protoscolex motility assay. The standard drugs albendazole, buparvaquone, mefloquine, MMV665807, monepantel, niclosamide and nitazoxanide were included. MMV665807, niclosamide and nitazoxanide were active against the parasite in all four assays against both species. MMV665807 and monepantel were significantly more active against E. multilocularis metacestode vesicles, while albendazole and nitazoxanide were significantly more active against E. multilocularis GL cells. Albendazole displayed activity against E. multilocularis GL cells, but no effects were seen in albendazole-treated E. granulosus s.s. GL cells within five days. Treatment of protoscoleces with albendazole and monepantel had no impact on motility. Similar results were observed for both species with praziquantel and its enantiomers against protoscoleces. In conclusion, in vitro culture techniques and drug screening methods previously established for E. multilocularis were successfully implemented for E. granulosus s.s., allowing comparisons of drug efficacy between the two species.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The susceptibility analysis of Echinococcus multilocularis protoscoleces tubulin to mebendazole and RNA interference
Qiqi Shi, Lele Huo, … Haobing Zhang·bioRxiv·Sep 24, 2020
- Repurposing Niclosamide Ethanolamine for Alveolar Echinococcosis Reveals a Disconnect Between In Vitro Efficacy and In Vivo Outcome
Matías Preza, Nicole L. Dietrich, … Britta Lundström‐Stadelmann·bioRxiv·Feb 10, 2026
- EgGLUT1 is crucial for the viability of larvae of Echinococcus granulosus sensus lato by involving its glucose uptake
K. Amahong, M. Yan, … G. Lü·bioRxiv·Apr 2, 2021
- Persistence of regenerative stem cells provides a cellular basis for the parasitostatic activity of albendazole against Echinococcus multilocularis
Monika Bergmann, Markus Spiliotis, … Klaus Brehm·bioRxiv·Sep 16, 2026
- Targeting Echinococcus multilocularis PIM kinase for improving anti-parasitic chemotherapy
- Investigation of the threonine metabolism of Echinococcus multilocularis: the threonine dehydrogenase as a potential drug target in alveolar echinococcosis
Marc Kaethner, Pascal Zumstein, … Britta Lundström‐Stadelmann·International Journal for Parasitology Drugs and Drug ResistancePeer-reviewed·Jan 18, 2025